Opinion|Videos|June 19, 2024
PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access
In their closing remarks, the panel shares their view on the future of prescription digital therapeutics and the prospects for the widespread adoption and implementation of these therapeutics in health care systems.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How can payers work with providers to establish protocols for appropriate PDT prescribing and monitoring efficacy?
- What opportunities exist for collaborative demonstration projects across payers, providers, manufacturers, and other stakeholders to generate evidence on optimal implementation strategies?
- How might PDTs potentially help mitigate or reduce healthcare disparities and inequities in access to treatment or health outcomes across different populations?
- How important is it that Congress pass the Access to Prescription Digital Therapeutics Actas you consider the long-term value PDTs can have on improving care to patients?
Advertisement
Related to this article
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.
Stigma, years-long diagnostic delays, and limited follow-up after a crisis remain hurdles for people with serious mental illness, experts say.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Labial gland biopsy may support diagnosis of neurologic Sjögren disease, especially when antibody tests are negative or inconclusive.
Advertisement
Advertisement
Trending on AJMC
1
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5